BRPI0507960A - métodos terapêuticos empregando precursores de óxido nìtrico - Google Patents
métodos terapêuticos empregando precursores de óxido nìtricoInfo
- Publication number
- BRPI0507960A BRPI0507960A BRPI0507960-8A BRPI0507960A BRPI0507960A BR PI0507960 A BRPI0507960 A BR PI0507960A BR PI0507960 A BRPI0507960 A BR PI0507960A BR PI0507960 A BRPI0507960 A BR PI0507960A
- Authority
- BR
- Brazil
- Prior art keywords
- carbamyl phosphate
- nitric oxide
- therapeutic methods
- oxide precursors
- methods employing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
MéTODOS TERAPêUTICO EMPREGANDO PRECURSORES DE óXIDO NìTRICO Moléculas de polinucleotídeo isoladas e peptídeos codificados por essas moléculas são usados na análise de fenótipos de sintetase I de carbamil fosfato humano, bem como o diagnóstico e aplicações terapêutica referente a um polimorfismo da sintease I de carbamil fosfato humano. Através de análises do DNA genómico ou DNA genómico amplificado ou cDNA amplificado derivado de mRNA, é possível tipificar uma sintetase I de carbamil fosfato humano com relação ao polimorfismo de sintetase I de carbamil fosfato humano, por exemplo, no contexto de diagnóstico e tratamento de doença veno-oclusiva hepática (HVOD) associada a transplantes de medula óssea.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/785,374 US9486429B2 (en) | 1999-06-01 | 2004-02-24 | Therapeutic methods employing nitric oxide precursors |
PCT/US2005/006081 WO2005082042A2 (en) | 2004-02-24 | 2005-02-24 | Therapeutic methods employing nitric oxide precursors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507960A true BRPI0507960A (pt) | 2007-07-17 |
Family
ID=34911448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507960-8A BRPI0507960A (pt) | 2004-02-24 | 2005-02-24 | métodos terapêuticos empregando precursores de óxido nìtrico |
Country Status (9)
Country | Link |
---|---|
US (2) | US9486429B2 (pt) |
EP (3) | EP3351241A1 (pt) |
JP (5) | JP2007524695A (pt) |
CN (1) | CN1946388B (pt) |
AU (2) | AU2005216270A1 (pt) |
BR (1) | BRPI0507960A (pt) |
IL (4) | IL177224A (pt) |
WO (1) | WO2005082042A2 (pt) |
ZA (2) | ZA200606575B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
WO2007095716A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
DE102006021406B4 (de) * | 2006-05-08 | 2008-08-07 | B.R.A.H.M.S Aktiengesellschaft | In vitro Verfahren zur Früherkennung von arznei- und suchtmittelinduzierten Leberschäden und zur Erkennung der bereits erreichten Stufe der Leberschädigung |
FR2907011B1 (fr) * | 2006-10-17 | 2010-05-14 | Univ Paris Descartes | Utilisation de la citrulline pour le traitement des etats de denutrition |
US7844609B2 (en) | 2007-03-16 | 2010-11-30 | Expanse Networks, Inc. | Attribute combination discovery |
FR2913885B1 (fr) * | 2007-03-22 | 2012-07-20 | Univ Paris Descartes | Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines |
HUE045571T2 (hu) * | 2008-01-31 | 2020-01-28 | Univ Vanderbilt | Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények |
AU2014204490B2 (en) * | 2008-01-31 | 2016-05-12 | Vanderbilt University | Therapeutic treatment for lung condtions |
JP2011511006A (ja) * | 2008-01-31 | 2011-04-07 | バンダービルト・ユニバーシティ | 肺病態に対する治療 |
JP5882735B2 (ja) | 2008-09-19 | 2016-03-09 | ネステク ソシエテ アノニム | 抗癌治療の間の骨髄麻痺又は好中球減少を阻止又は緩和するための栄養支援 |
US8108406B2 (en) | 2008-12-30 | 2012-01-31 | Expanse Networks, Inc. | Pangenetic web user behavior prediction system |
EP3276526A1 (en) | 2008-12-31 | 2018-01-31 | 23Andme, Inc. | Finding relatives in a database |
WO2011051742A1 (en) * | 2009-10-28 | 2011-05-05 | Modutech S.A. | Preparation comprising amino acids and plants and its activity in the alcohol detoxification |
US9572848B1 (en) | 2014-03-26 | 2017-02-21 | Aemes Research L.L.L.P. | Composition of matter for sexual dysfunction |
RU2733738C2 (ru) | 2015-06-29 | 2020-10-06 | Вандербилт Юниверсити | Внутривенное введение цитруллина во время хирургического вмешательства |
US10265286B2 (en) * | 2016-12-28 | 2019-04-23 | Vanderbilt University | Sequelae of cardiopulmonary bypass-induced pulmonary injury |
JP2018114414A (ja) * | 2018-05-07 | 2018-07-26 | 株式会社大一商会 | 遊技機 |
EP3930836A4 (en) * | 2019-02-27 | 2022-10-05 | The Regents of the University of Michigan | CARBAMOYL PHOSPHATE SYNTHASE-1 FOR THE TREATMENT AND PREVENTION OF INTERNAL TISSUE INJURIES |
WO2020247853A1 (en) * | 2019-06-05 | 2020-12-10 | Asklepion Pharmaceuticals, Llc | Improved method of synthesis and purification of citrulline |
US20230404956A1 (en) * | 2022-06-21 | 2023-12-21 | Asklepion Pharmaceuticals Llc | Therapeutic window for citrulline therapy |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1005A (en) * | 1838-11-12 | Ing and heating booms and other apabtments beqtjibing abtrficial | ||
ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
NL8102724A (nl) | 1980-07-11 | 1982-02-01 | Stamicarbon | Werkwijze voor de bereiding van copolymeren van etheen met tenminste een ander 1-alkeen. |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4769331A (en) * | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5573933A (en) * | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
US4996236A (en) * | 1988-06-22 | 1991-02-26 | Takeda Chemical Industries, Ltd. | Therapeutic composition for hepatic encephalopathy |
US5162215A (en) * | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5286634A (en) * | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5614396A (en) * | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5489742A (en) * | 1990-10-23 | 1996-02-06 | Board Of Regents, The University Of Texas System | Transgenic rats and animal models of inflammatory disease |
JPH06504671A (ja) * | 1990-12-04 | 1994-06-02 | ボード・オヴ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | Neuを介して起こるトランスフォーメーションの抑制方法とそのための組成物 |
US5641484A (en) * | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
US5643567A (en) * | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
EP1875917A3 (en) * | 1990-12-05 | 2012-11-28 | The General Hospital Corporation | Use of NO for the treatment or prevention of reversible pulmonary vasoconstriction |
US5550316A (en) * | 1991-01-02 | 1996-08-27 | Fox Chase Cancer Center | Transgenic animal model system for human cutaneous melanoma |
US5550024A (en) * | 1991-04-19 | 1996-08-27 | Biotechnology Research & Development Corporation | Genetic markers for pig litter size |
US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
US5286739A (en) * | 1991-09-27 | 1994-02-15 | Board Of Regents, University Of Texas System | Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
WO1994016740A1 (en) | 1993-01-29 | 1994-08-04 | Brigham And Women's Hospital | The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5646008A (en) * | 1993-06-22 | 1997-07-08 | The Regent Of The University Of Michigan | Vertebrate apoptosis gene: compositions and methods |
US5625125A (en) * | 1994-08-09 | 1997-04-29 | Dnx Biotherapeutics | Phospholipase A2 expressing transgenic animals |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5648061A (en) * | 1995-05-24 | 1997-07-15 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5874471A (en) * | 1997-02-27 | 1999-02-23 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
US6028107A (en) * | 1997-02-27 | 2000-02-22 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
US6796966B2 (en) * | 1997-10-15 | 2004-09-28 | Jeffrey E. Thomas | Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal |
US6358536B1 (en) * | 1997-10-15 | 2002-03-19 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
US6182295B1 (en) * | 1999-06-14 | 2001-02-06 | Kevin Sciglia | Hat |
AU761271B2 (en) * | 1999-11-15 | 2003-05-29 | Lg Electronics Inc. | Union device for dust-box in cyclone type vacuum cleaner |
JP3506114B2 (ja) | 2000-01-25 | 2004-03-15 | 株式会社ニコン | モニタ装置及びこのモニタ装置を具えた研磨装置及び研磨方法 |
US6689810B2 (en) * | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
EP1448600A4 (en) * | 2001-09-07 | 2004-12-22 | Bristol Myers Squibb Co | POLYNUCLEOTIDE ENCODING A NOVEL HUMAN G PROTEIN-RELATED RECEPTOR, HGPRMBY39 |
US20030134332A1 (en) * | 2001-11-28 | 2003-07-17 | Boykin Joseph V. | Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
DK1841458T3 (da) * | 2005-01-06 | 2012-04-23 | Discovery Lab Inc | Behandlingsregime med overfladeaktivt stof til behandling eller forebyggelse af bronkopulmonal dysplasi |
EP1957657A4 (en) * | 2005-12-01 | 2009-02-18 | Nps Pharma Inc | BIOMARKER OF ENHANCED INTESTINAL FUNCTION |
JP2011511006A (ja) * | 2008-01-31 | 2011-04-07 | バンダービルト・ユニバーシティ | 肺病態に対する治療 |
HUE045571T2 (hu) * | 2008-01-31 | 2020-01-28 | Univ Vanderbilt | Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények |
-
2004
- 2004-02-24 US US10/785,374 patent/US9486429B2/en not_active Expired - Lifetime
-
2005
- 2005-02-24 EP EP18158829.4A patent/EP3351241A1/en not_active Ceased
- 2005-02-24 JP JP2006554329A patent/JP2007524695A/ja active Pending
- 2005-02-24 AU AU2005216270A patent/AU2005216270A1/en not_active Abandoned
- 2005-02-24 BR BRPI0507960-8A patent/BRPI0507960A/pt not_active Application Discontinuation
- 2005-02-24 EP EP10184493A patent/EP2319507A1/en not_active Ceased
- 2005-02-24 CN CN2005800126935A patent/CN1946388B/zh active Active
- 2005-02-24 WO PCT/US2005/006081 patent/WO2005082042A2/en active Application Filing
- 2005-02-24 EP EP05723789A patent/EP1718289A4/en not_active Withdrawn
-
2006
- 2006-08-02 IL IL177224A patent/IL177224A/en active IP Right Grant
- 2006-08-07 ZA ZA2006/06575A patent/ZA200606575B/en unknown
-
2008
- 2008-07-18 ZA ZA2008/06276A patent/ZA200806276B/en unknown
-
2009
- 2009-07-31 AU AU2009203177A patent/AU2009203177B2/en active Active
-
2012
- 2012-09-13 JP JP2012201762A patent/JP2013040176A/ja active Pending
-
2013
- 2013-04-23 IL IL225912A patent/IL225912A/en active IP Right Grant
- 2013-06-13 IL IL225911A patent/IL225911A/en active IP Right Grant
-
2014
- 2014-04-27 IL IL232265A patent/IL232265A0/en unknown
- 2014-08-15 JP JP2014165456A patent/JP2015007090A/ja active Pending
-
2015
- 2015-11-30 JP JP2015232749A patent/JP6239571B2/ja active Active
-
2016
- 2016-11-04 US US15/343,998 patent/US20170119715A1/en not_active Abandoned
-
2017
- 2017-08-08 JP JP2017152929A patent/JP6395912B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN1946388A (zh) | 2007-04-11 |
EP2319507A1 (en) | 2011-05-11 |
IL177224A0 (en) | 2006-12-10 |
WO2005082042A2 (en) | 2005-09-09 |
AU2005216270A1 (en) | 2005-09-09 |
CN1946388B (zh) | 2012-03-07 |
JP2018024665A (ja) | 2018-02-15 |
EP1718289A2 (en) | 2006-11-08 |
US20170119715A1 (en) | 2017-05-04 |
IL177224A (en) | 2014-05-28 |
AU2009203177A1 (en) | 2009-08-20 |
IL225912A0 (en) | 2013-06-27 |
JP2013040176A (ja) | 2013-02-28 |
EP3351241A1 (en) | 2018-07-25 |
JP2015007090A (ja) | 2015-01-15 |
ZA200606575B (en) | 2012-10-31 |
IL225911A0 (en) | 2013-06-27 |
EP1718289A4 (en) | 2007-04-11 |
AU2009203177B2 (en) | 2012-03-22 |
ZA200806276B (en) | 2012-12-27 |
JP2016074709A (ja) | 2016-05-12 |
IL225912A (en) | 2015-07-30 |
WO2005082042A3 (en) | 2006-05-04 |
JP2007524695A (ja) | 2007-08-30 |
JP6239571B2 (ja) | 2017-11-29 |
IL232265A0 (en) | 2014-06-30 |
IL225911A (en) | 2015-05-31 |
US20040235953A1 (en) | 2004-11-25 |
JP6395912B2 (ja) | 2018-09-26 |
US9486429B2 (en) | 2016-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507960A (pt) | métodos terapêuticos empregando precursores de óxido nìtrico | |
EP1690535A3 (en) | Therapeutic use of nitric oxide precursor | |
WO2006135684A3 (en) | Methods and kits for sense rna synthesis | |
PE20120015A1 (es) | Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico | |
MX2009008139A (es) | Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos. | |
ATE494588T1 (de) | Verfahren zur mikrorna-identifikation und ihrer anwendungen bei der forschung und menschlichen gesundheit | |
BRPI0511479A (pt) | molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis | |
WO2005100998A3 (en) | Membrane markers for use in cancer diagnosis and therapy | |
WO2008151803A3 (en) | New polymorphisms in abcb1 associated with a lack of clinical response to medicaments | |
DE60325016D1 (de) | Oligonukleotide mit alternierenden segmenten und deren verwendungen | |
MY142067A (en) | Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease | |
NZ543467A (en) | The severe acute respiratory syndrome coronavirus | |
WO2007058968A3 (en) | Gene expression profiles and methods of use | |
WO2005059108A3 (en) | Gene expression profiles and methods of use | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2008070666A3 (en) | Compositions and methods to treat cancer with cpg rich dna and cupredoxins | |
WO2005032495A8 (en) | Gene expression profiles and methods of use | |
WO2009106819A3 (en) | Biological materials and uses thereof | |
ATE548454T1 (de) | Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis | |
WO2005040421A3 (en) | Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues | |
ATE533501T1 (de) | Verwendung des ped-faktors zur induktion von zellregenerierung | |
Sharif-Zak et al. | CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender | |
TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
MX2011006773A (es) | Biomarcador. | |
FI20022064A0 (fi) | Nukleiinihappokoettimia, universaaleja alukkeita ja menetelmiä, joissa niitä käytetään |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |